Home › Funds › Aisling Capital Management LP › GLUE
Aisling Capital Management LP position in GLUE
MONTE ROSA THERAPEUTICS INC · Health Care
Aisling Capital Management LP reported holding 1,555,664 shares of GLUE (MONTE ROSA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$18.6M, representing 6.20% of its reported portfolio and ranking #4 among its reported holdings. Aisling Capital Management LP has disclosed GLUE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Aisling Capital Management LP's GLUE position evolved
Aisling Capital Management LP first disclosed a stake in GLUE in Q3 2023 at 1,472,331 shares (US$7.1M). The position peaked in Q2 2026 at 1,555,664 shares, worth US$37.6M. Across 13 filings, Aisling Capital Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 1,555,664 shares valued at US$18.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.47M | $7.05M | New |
| Q4 2023 | 1.47M | $8.32M | Hold |
| Q1 2024 | 1.47M | $10.38M | Hold |
| Q2 2024 | 1.47M | $5.51M | Hold |
| Q3 2024 | 1.47M | $7.80M | Hold |
| Q4 2024 | 1.47M | $10.22M | Hold |
| Q1 2025 | 1.47M | $6.83M | Hold |
| Q2 2025 | 1.47M | $6.64M | Hold |
| Q3 2025 | 1.47M | $10.91M | Hold |
| Q4 2025 | 1.47M | $23.09M | Hold |
| Q1 2026 | 1.56M | $25.59M | Add |
| Q2 2026 | 1.56M | $37.65M | Hold |
| Q3 2026 | 1.56M | $18.56M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GLUE and 13F data
GLUE (MONTE ROSA THERAPEUTICS INC) is a Health Care company. 65 other funds we track also report a position in GLUE — the largest reported positions include NEA Management Company, LLC (US$186.2M), TCG Crossover Management, LLC (US$111.9M), Vestal Point Capital, LP (US$111.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GLUE
- NEA Management Company, LLC 7.69M sh · $186.15M · Q2 2026
- TCG Crossover Management, LLC 4.62M sh · $111.86M · Q2 2026
- Vestal Point Capital, LP 4.60M sh · $111.32M · Q2 2026
- BVF INC/IL 4.46M sh · $107.95M · Q2 2026
- BAKER BROS. ADVISORS LP 4.35M sh · $105.17M · Q2 2026
- MONTANOVA CAPITAL, LLC 3.55M sh · $85.90M · Q2 2026
- Versant Venture Management, LLC 3.18M sh · $76.97M · Q2 2026
- BRAIDWELL LP 2.45M sh · $59.33M · Q2 2026
- Bellevue Group AG 1.19M sh · $28.80M · Q2 2026
- MPM BioImpact LLC 1.16M sh · $28.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.00M sh · $24.20M · Q2 2026
- Nextech Invest Ltd. 761.15K sh · $18.42M · Q2 2026
More on Aisling Capital Management LP
FAQ
How long has Aisling Capital Management LP held GLUE?
Aisling Capital Management LP has disclosed GLUE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Aisling Capital Management LP's current position in GLUE?
As of Q3 2026, Aisling Capital Management LP holds 1.56M shares of GLUE (MONTE ROSA THERAPEUTICS INC), valued at $18.56M, representing 6.20% of its reported portfolio and ranking #4.
Has Aisling Capital Management LP been buying or selling GLUE?
In the latest 13F filing (Q3 2026), Aisling Capital Management LP held unchanged its position in GLUE. The position peaked in Q2 2026 at 1.56M shares.
Which other funds hold GLUE?
Other major institutional holders of GLUE include NEA Management Company, LLC, TCG Crossover Management, LLC, Vestal Point Capital, LP, among 65 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.